Dermapharm Holding

Dermapharm is a Grünwald-based specialty pharmaceutical company that owns over 700 marketing authorizations for branded off-patent prescription drugs and OTC products — the kind of unglamorous portfolio that includes Vitamin D supplements (the German market-leading Dekristol brand), corticosteroid creams, anti-allergy nasal sprays, and oral contraceptives. From 2020 to 2022 Dermapharm enjoyed a windfall as the contract manufacturing partner for BioNTech mRNA COVID vaccine fill-and-finish — at peak the contract generated EUR 320M annual revenue and pushed group operating margin above 30%. When the COVID order book collapsed in 2023, revenue dropped, margins compressed back toward the underlying 22% base rate, and the stock fell 60% from EUR 81 to EUR 31 as the market tried to discount the post-vaccine normalisation. The 2024–2025 transition was painful but clean: the BioNTech tail rolled off, EUR 70M of integration costs from the Montavit and Arkopharma acquisitions were absorbed, and underlying branded-pharma growth in dermatology, allergy and pain-management portfolios resumed at 4–6% organic. 2025 revenue grew 4.5% with earnings +35.5% YoY as one-time costs annualised out. The stock recovered to EUR 51.80 — the 52-week high — but is still 36% below the 2022 peak. Family founder Wilhelm Beier remains chairman with 50.1% stake through Themis Beteiligungs-Aktiengesellschaft.

Dermapharm is not on smart-money 13F filings (US disclosure regime does not catch German mid-caps) but the European institutional ownership is concentrated and patient. Wilhelm Beier and the founding family hold 50.1% through Themis Beteiligungs-Aktiengesellschaft — voting control plus skin-in-the-game on every strategic decision. Free float is roughly 49% with Union Investment (Frankfurt mutual fund family) at 7.2%, DWS at 5.4%, Deka at 4.1%, Allianz Global Investors at 3.6%. Family-controlled German healthcare specialty stocks have historically produced superior long-term returns versus broader DAX (Stada, Merck KGaA, Sartorius all show similar patterns). The interesting accumulation signal is from Norges Bank Investment Management — the Norwegian sovereign wealth fund crossed 5% disclosure threshold in Q3/2025, having steadily added through the 2023–2024 drawdown. Short interest is irrelevant at under 1% — German specialty pharma is essentially un-shorted because the family overhang would make any squeeze costly. The smart-money read here is family alignment plus quiet long-term sovereign accumulation.

DMP.DE trades at EUR 51.80 with forward P/E 17.71 on 2026 EPS consensus of EUR 2.93. EV/EBITDA 12.3x (incorporating EUR 670M net debt). Compare: Sandoz fwd P/E 20x, Recordati 22x, Hikma Pharmaceuticals 14x, Stoxx Europe Healthcare 18.4x median. DMP sits at the cheap end of European specialty pharma. 52-week range EUR 31.70–51.80; today is the high. Mean analyst target EUR 47.88 implies -7.6% — the sell-side already views the recovery rally as overdone in the short term. Bull case (continued 5% organic + EUR 200M of M&A annually + multiple to 20x) supports EUR 65 in 18 months. Bear case (BioNTech-tail completion drags 2026 vs 2025 comps, debt refinancing absorbs EPS upside, multiple to 15x) supports EUR 41. Risk/reward at EUR 51.80 is +26% / -21% — symmetric, not asymmetric. This is a hold, not a screaming buy at current levels.

1. Jul 2026: H1/2026 results — first half without BioNTech comp tailwind. Confirms whether 5% organic underlying growth is durable.
2. Sep 2026: Annual investor day — typical venue for new M&A pipeline disclosure and capital allocation update.
3. Q1 2027: EUR 350M Schuldschein refinancing window opens — first quantitative datapoint on the rate headwind.

Dermapharm is a well-run family pharma compounder that has fully recovered from the BioNTech post-COVID transition. The hard work is done: integration costs absorbed, debt rolled, underlying portfolio re-accelerating at 5% organic. The bull case is straightforward — buy a 22%-operating-margin pharma compounder with founder ownership at 17.7x forward earnings and let it compound at 8–10% annually through dividends and modest M&A accretion. The problem at EUR 51.80 is that the easy money has been made. The stock more than doubled from the EUR 22 lows in late 2023 and now trades above the consensus target. I would not chase here. A pullback to EUR 44–46 (the 200-day moving average plus a small margin) would re-set risk/reward to +40%/-10% and become a serious buy. For now, this is on my watchlist with patience for the next earnings cycle.